View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2022

Yamo Pharma doses first subject in Phase II autism spectrum disorder trial

The multicentre, randomised trial of L1-79 will enrol nearly 50 subjects of the age 12 to 21 years.

Yamo Pharmaceuticals has enrolled and dosed the first subject in a Phase II clinical trial of L1-79 in adolescents and young adults with autism spectrum disorder (ASD).

The enrolment commenced at six research centres in the US. 

An inhibitor of tyrosine hydroxylase, L1-79 can enhance the socialisation and communication symptoms by regulating the catecholaminergic pathways associated with ASD.

With a two-period, placebo-controlled crossover design, the multicentre, randomised, chronic-dosing Phase II trial will enrol nearly 50 subjects of the age 12 to 21 years.

These subjects will be randomised into a 1:1 ratio to one of two active therapy arms groups to receive 200mg or 300mg dose of L1-79. 

On day one of Period 1, subjects in each dosing arm will be randomised and given either L1‑79 or placebo twice a day for 12 weeks. 

On concluding this period, participants will washout for six weeks and will then be crossed over into Period 2.

Subjects who were given a placebo in Period 1 will receive L1‑79 and vice versa for another 12 weeks in Period 2.

Assessment of L1-79’s effect on the key deficits in social communication and interaction as analysed using the BOSCC, Vineland Adaptive Behavior Scale Third Edition (Vineland-3), CGI-S and other social-communication interaction measures are the key goals of the trial.

Yamo CEO Chuck Bramlage said: “The design of this clinical trial builds on the insights gained in previous clinical experience with L1-79, in which a favourable tolerability profile and positive efficacy trends were observed in a smaller 28-day pilot study. 

“The ongoing Phase II study will serve as a proof-of-concept to evaluate the impact of two doses of L1-79 in a placebo-controlled crossover study with two 12-week treatment periods in 50 adolescents and adults with ASD.” 

Currently, the only drugs approved by the US Food and Drug Administration for ASD are intended to treat irritability linked to autism. 

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy